Avacta Share Discussion Threads

[lantanatony] 28/6/2018 14:26

Why can't Avacta do a deal with revenue attached?
Does anyone know the answer?

[catch007] 27/6/2018 22:21

Interesting video with Alistair Smith....the focus is on licensing partners with some 25 parties now engaged in evaluations. Deals to struck 2018/9 we will see if that happens. End of year cash forecast 6m in the Bank

hxxp://www.biotech-capital.com/companies/stocktube/9584/avacta-group-plc-focused-on-securing-third-party-deals-for-both-sides-of-the-business-9584.html

[lantanatony] 11/6/2018 20:49

So,what has sent the Avacta shares down another six percent today?
Is it the appointment of Dr Forster or that Dr Nichols remains a Director?

[lantanatony] 31/5/2018 21:24

The Avacta claims about great interest from the sector just don't seem to stand up.
Unless of course they are holding back information regarding sector interest.
However,that would be wrong?
So the Question is, what is going on at Avacta?
Affimers have been around for long enough now for the sector to understand their VALUE?!
Yet no deals are being done on this ground braking technology!

Meanwhile,Shareholder relations are at a very low ebb,the Brokers are poor and the management is weak.
How do their major shareholder,the IP Group hold their heads up in the City?!
Is it that they are so used to similar disasters in their portfolio that they have not noticed?

[banksy9] 24/5/2018 09:07

Back to Avacta - looks like a dead cat bounce before the next fundraise...…..

[banksy9] 24/5/2018 09:04

MIPs look interesting but are still a very long way from the clinic, I suspect...…230;..

[wan] 23/5/2018 08:41

I have previously highlighted MIPs Diagnostics on here, so I believe the following is noteworthy -

Dr. Adrian Kinkaid, CEO of MIPs Diagnostics

Adrian has extensive experience in the life sciences sector, with particular expertise in affinity reagents, including antibodies, affimers and aptamers. He has developed a thorough understanding of the field and considers MIPs as a cost effective and high quality alternative to existing reagents due especially to their robustness and speed of development.

Prior to joining MIP Diagnostics, Adrian worked as Chief Commercial Officer for Promexus, a protein biotherapeutics company based on affimer technology from Avacta Life Sciences. Before this he was Head of Technology Access and then Strategic Market Development Leader for Abcam, the leading provider of research antibodies.

Mercia further invests in MIPs Diagnostics (another potential game changer in Mercia's portfolio that's on my watch list!) -

‘Synthetic antibody’ firm MIP Diagnostics secures £1.5m
By Tess Egginton - 9th May 2018

A Midlands-based life sciences company which develops synthetic alternatives to antibodies has closed a £1.5m Series A funding round supported by Mercia Fund Managers and a number of private investors.

The investment will allow MIP Diagnostics to expand its team, set up new production facilities and develop its own products to sell under license.

New antibodies can take months to make and the process can be unreliable, as it involves ‘challenging’ cells with an antigen or foreign molecule in the hope that it will produce the right antibodies.

By contrast MIPs are synthesized in a laboratory and can be created in days. They are also more cost-effective and much more stable than antibodies, with a longer shelf-life and can be used in conditions where antibodies just will not function.

Full story -

Also not widely reported, is that David Evan's is another new investor in MIPs -

[pugugly] 22/5/2018 16:36

Weak holders getting out on the bounce and day traders grabbing a small profit -
Do I smell buring fingers from all who bought at 34p and above ??

Could this ramp up and fall back suggest a placing might be round the corner or am I just paranoid?

[18bt] 22/5/2018 08:28

More promising studies, but no deal yet

[lantanatony] 16/5/2018 18:21

More importantly,there are no deals being done.
Despite the bullish statements from the Company.
Maybe the Directors should have another look a the "YELLOW BOOK."

[banksy9] 16/5/2018 16:35

It says the company can't convince enough shareholders not to want to sell and/or enough new shareholders to buy. Simple.

[escapetohome] 14/5/2018 21:06

Come on now avacta this is silly, what does this sort of share price say about the running of the company?? Not good.

I would get it sorted.

Thats my very strong advice indeed.

Nudge Nudge Wink Wink!!!!

[banksy9] 11/5/2018 17:35

Here's the answer: www.capitalnetwork.com/companies/research/110600/avacta-group-rapid-progress-of-immuno-oncology-programs-110600.html.

"Stock price weakness reflects in our view uncertainty around a likely capital raise before year end". So, if they need another 2-years' cash to get to the clinic in 2020 they will need another £20m or so, which is about another 50% dilution or so........

[banksy9] 10/5/2018 09:54

Who knows? I suspect the elephant in the room might well be the need to raise more capital but that's just a guess. The question is how much and a what price.......? Thoughts? It gets very expensive in the clinic!

[lantanatony] 09/5/2018 22:46

With the shares below thirty pence.
When can we expect some proactive reaction from the Directors!?

[banksy9] 02/5/2018 05:25

Agreed, the Prof. needs to do some deals or step aside to get a commercial leader in ASAP.

[lantanatony] 30/4/2018 08:21

Yes ,Avacta need to stop talking and start doing.
If they ever needed a deal it's now.

[banksy9] 28/4/2018 19:08

Yes they originally promised a revenue-generation story with web-based sales that never materialised and then flipped into a therapeutic story but still 2 years from the clinic.

I'd wait for a very good discount at the next fundraise........

[escapetohome] 27/4/2018 07:40

And yet they have been many many years on aim already, but its as though they just got a listing with their science.

Time to buy?

[banksy9] 27/4/2018 04:03

Oil and water, my friend, although I'm not suggesting which is the oily side! This looks like a classic academic spinout with good science that has come on to AIM too early. Investors want it to be a revenue-generating business when more research is required to hit a serious value inflection point. The problem is they'll need a lot of cash by the looks of it. Prepare for mega dilution guys!

[lantanatony] 24/4/2018 16:10

Academia and business just don't seem compatible!?

[ffp] 18/4/2018 20:16

Liked that

[dickdastardly1] 18/4/2018 20:15

I agree with Poacher: Professor Smith likes to talk the talk on the webcam, burn the cash but can't do deals whatever the technology. As they say, you can take the academic out the lab but you can't take the lab out the academic! Look like another fund raising is on the way and the cycle starts all over again. DD

[lantanatony] 17/4/2018 14:46

Crazy!
Avacta raised their funding at £1,20.
What do you think those investors think ?

[escapetohome] 17/4/2018 12:49

You wouldnt think so at all.

I think it should be recognised that some progress has been made.

Perhaps not financially, but sadly some investors are churning out the negative record, solely because they bought at much higher prices!!!!!!!!!!!